Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia
Sponsor: Merck Sharp & Dohme LLC
A PHASE3 clinical study on Mixed Hyperlipidemia, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.